secwatch.observer — SEC 8-K summary
======================================

Issuer:     Savara Inc (SVRA)
CIK:        0001160308
Form:       8-K
Filed at:   2026-01-27T23:59:59+00:00
Accession:  0001193125-26-023378
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03
LLM model:  deepseek-v4-flash:cloud@v2

Savara amends Hercules loan; adds $75M drawdown tied to FDA approval of MOLBREEVI
--------------------------------------------------------------------------------

- Amends $105M loan agreement; new $45M and $30M tranches available upon FDA approval of MOLBREEVI for aPAP.
- First Post-Approval Tranche of $45M must be drawn within 120 days or by June 30, 2027.
- Second $30M tranche available after first tranche drawn or expired, same deadline.
- Financial covenant compliance dates extended: unrestricted cash to Apr 2027, revenue covenant to Sep 2027 if market cap low.
- Lenders granted first-priority security interest in IP, converting to negative pledge if RTW Purchase Agreement terminated and $50M+ cash held.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1160308/000119312526023378/0001193125-26-023378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1160308/000119312526023378/d39349d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-023378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer